Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096746 · ClinicalTrials.gov registry record
Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 200
- Enrollment target
NCT00096746 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 200 participants.
The verdict
NCT00096746 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
This study will compare the response of subjects who failed a first-line ATV-containing regimen and who have the 150L-containing virus to subsequent protease inhibitor (PI)-containing therapy with that of a cohort who has failed a first-line reverse transcriptase inhibitor (NNRTI), and is subsequently receiving PI-containing therapy.
Interventions
- DRUG LPV/RTV + 2NRTIs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096746
The ClinicalTrials.gov registry entry for NCT00096746 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LPV/RTV + 2NRTIs is the first listed.
NCT00096746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096746 about?
NCT00096746 is a clinical study titled "Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects". This study will compare the response of subjects who failed a first-line ATV-containing regimen and who have the 150L-containing virus to subsequent protease inhibitor (PI)-containing therapy with that of a cohort who has failed a first-line reverse transcriptase inhibitor (NNRTI), and is subsequent...
What is the current status of trial NCT00096746?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2004-11. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00096746?
The interventions under investigation include: LPV/RTV + 2NRTIs (DRUG).
Who is sponsoring clinical trial NCT00096746?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.